iRadimed (NASDAQ:IRMD) Issues Q1 2026 Earnings Guidance

iRadimed (NASDAQ:IRMD) issued an update on its first quarter 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.440-0.480 for the period, compared to the consensus estimate of 0.440. The company issued revenue guidance of $21.0 million-$22.0 million, compared to the consensus revenue estimate of $20.8 million. iRadimed also updated its FY 2026 guidance to 2.060-2.210 EPS.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on IRMD. Lake Street Capital reissued a “buy” rating and issued a $100.00 target price on shares of iRadimed in a research note on Monday, November 3rd. Zacks Research raised shares of iRadimed to a “hold” rating in a report on Tuesday, November 4th. Wall Street Zen cut shares of iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Finally, Roth Mkm set a $90.00 target price on iRadimed in a report on Friday, October 31st. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $95.00.

iRadimed Price Performance

IRMD stock opened at $95.97 on Tuesday. The business has a 50 day simple moving average of $97.82 and a two-hundred day simple moving average of $83.09. iRadimed has a 1-year low of $47.48 and a 1-year high of $104.93. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of 58.16 and a beta of 1.11.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.05. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. The business had revenue of $22.69 million during the quarter, compared to analysts’ expectations of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Sell-side analysts anticipate that iRadimed will post 1.66 EPS for the current fiscal year.

iRadimed Announces Dividend

The company also recently announced a special dividend, which was paid on Tuesday, December 30th. Shareholders of record on Wednesday, December 17th were issued a $0.50 dividend. The ex-dividend date was Wednesday, December 17th. iRadimed’s dividend payout ratio is currently 41.21%.

Insider Buying and Selling at iRadimed

In other news, CEO Roger E. Susi sold 5,000 shares of the stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $100.65, for a total value of $503,250.00. Following the transaction, the chief executive officer directly owned 2,262,500 shares of the company’s stock, valued at approximately $227,720,625. This represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO John Glenn sold 15,000 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the completion of the transaction, the chief financial officer owned 7,362 shares of the company’s stock, valued at approximately $716,248.98. This represents a 67.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 55,000 shares of company stock valued at $5,287,900. Corporate insiders own 36.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Quarry LP acquired a new stake in iRadimed during the 3rd quarter valued at $40,000. Tower Research Capital LLC TRC boosted its position in shares of iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 495 shares during the period. Virtus Advisers LLC acquired a new position in shares of iRadimed during the third quarter worth $117,000. Aquatic Capital Management LLC grew its stake in shares of iRadimed by 210,400.0% during the third quarter. Aquatic Capital Management LLC now owns 2,105 shares of the medical equipment provider’s stock valued at $150,000 after acquiring an additional 2,104 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in iRadimed during the 3rd quarter worth approximately $164,000. 92.34% of the stock is owned by institutional investors and hedge funds.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.